Evidence map›Paper›PMID 41927576›Full record

ArticleNPJ vaccines2026

Cattle antibodies identify a cross-serotype broadly neutralising foot-and-mouth disease virus epitope.

Marie Bonnet-Di Placido, Helen M E Duyvesteyn, Angela W Steyn, Abigail L Hay, Claudine Porta, Kristel Ramirez Valdez, Elena Lokhman, Sylvia Crossley, Kevan Hanson, William N Mwangi and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Marie Bonnet-Di PlacidoThe Pirbright Institute, Pirbright, Surrey, UK.
Helen M E DuyvesteynDivision of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK.
Angela W SteynThe Pirbright Institute, Pirbright, Surrey, UK.
Abigail L HayThe Pirbright Institute, Pirbright, Surrey, UK.
Claudine PortaDivision of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK.
Kristel Ramirez ValdezThe Pirbright Institute, Pirbright, Surrey, UK.
Elena LokhmanThe Pirbright Institute, Pirbright, Surrey, UK.
Sylvia CrossleyThe Pirbright Institute, Pirbright, Surrey, UK.
Kevan HansonThe Pirbright Institute, Pirbright, Surrey, UK.
William N MwangiThe Pirbright Institute, Pirbright, Surrey, UK.
Danish MunirThe Pirbright Institute, Pirbright, Surrey, UK.
Eva Perez-MartinThe Pirbright Institute, Pirbright, Surrey, UK.
Nick J KnowlesThe Pirbright Institute, Pirbright, Surrey, UK.
Alison BurmanThe Pirbright Institute, Pirbright, Surrey, UK.
Abdelaziz A YassinThe Pirbright Institute, Pirbright, Surrey, UK.
Amin AsforThe Pirbright Institute, Pirbright, Surrey, UK.
Cristina FarallaAbCellera Biologics Inc, Vancouver, BC, Canada.
Katherine J LamAbCellera Biologics Inc, Vancouver, BC, Canada.
Róisín McCombAbCellera Biologics Inc, Vancouver, BC, Canada.
Carina LeifeldMSD Animal Health, Boxmeer, AN, The Netherlands.
Kimberly PieterszMSD Animal Health, Boxmeer, AN, The Netherlands.
Donald P KingThe Pirbright Institute, Pirbright, Surrey, UK.
Erwin van den BornMSD Animal Health, Boxmeer, AN, The Netherlands.
Sherie K DuncanAbCellera Biologics Inc, Vancouver, BC, Canada.
Bryan CharlestonThe Pirbright Institute, Pirbright, Surrey, UK.
Elizabeth E FryDivision of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK.
Jingshan RenDivision of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK.
David I StuartDivision of Structural Biology, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Headington, Oxford, UK. dave.stuart@strubi.ox.ac.uk.
John A HammondThe Pirbright Institute, Pirbright, Surrey, UK. john.hammond@pirbright.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Foot-and-mouth disease virus (FMDV) causes a devastating disease that threatens global food security. Vaccination is hindered by antigenic diversity across serotypes. To identify cross-serotype neutralising epitopes, we isolated 24 FMDV-specific antibodies from cattle sequentially vaccinated with antigens from four serotypes, of which three neutralised three vaccine strains. These three antibodies neutralised 21 and bound 59 additional topotypes across O, A, Asia 1, and C serotypes. Cryo-EM complexes of Fabs with FMD virus-like particles indicated all three recognise a common flexible epitope at the VP1 C-terminus, confirmed by binding competition. Crystallography and structural modelling revealed that a normally inaccessible surface of the hydrophobic VP1 C-terminal peptides inserts into a similar groove in all three antibodies. Comparison of neutralisation activity and integrin receptor blocking by whole antibodies, F(ab')

Identifiers

PMID41927576
PMCPMC13216289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.